2004
DOI: 10.3748/wjg.v10.i5.620
|View full text |Cite
|
Sign up to set email alerts
|

IL-10 and its related cytokines for treatment of inflammatory bowel disease

Abstract: Inflammatory bowel diseases (IBDs), including Crohn's disease and ulcerative colitis are chronic inflammatory disorders of gastrointestinal tract. Although the etiology is incompletely understood, initiation and aggravation of the inflammatory process seem to be due to a massive local mucosal immune response. Interleukin-10 (IL-10) is a regulatory cytokine which inhibits both antigen presentation and subsequent pro-inflammatory cytokine release, and it is proposed as a potent anti-inflammatory biological thera… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

2
145
0
2

Year Published

2007
2007
2024
2024

Publication Types

Select...
8
2

Relationship

0
10

Authors

Journals

citations
Cited by 225 publications
(149 citation statements)
references
References 50 publications
2
145
0
2
Order By: Relevance
“…IL-10 is mainly produced by regulatory T-cells and helps to down-regulate the production of pro-inflammatory cytokines (Moore et al, 2001). The importance of IL-10 in controlling the intestinal inflammation was shown by IL-10 deficient mice which eventually developed enterocolitis (Kuhn et al, 1993) or by beneficial therapeutic effects of IL-10 in human IBD and in experimental colitis (Li and He, 2004;Lindsay et al, 2004). However, there were no significant differences in IL-10 mRNA abundance in duodenum and colon between FRD, IBD and control groups, in accordance with earlier studies (German et al, 2000;Ridyard et al, 2002).…”
Section: Discussionmentioning
confidence: 99%
“…IL-10 is mainly produced by regulatory T-cells and helps to down-regulate the production of pro-inflammatory cytokines (Moore et al, 2001). The importance of IL-10 in controlling the intestinal inflammation was shown by IL-10 deficient mice which eventually developed enterocolitis (Kuhn et al, 1993) or by beneficial therapeutic effects of IL-10 in human IBD and in experimental colitis (Li and He, 2004;Lindsay et al, 2004). However, there were no significant differences in IL-10 mRNA abundance in duodenum and colon between FRD, IBD and control groups, in accordance with earlier studies (German et al, 2000;Ridyard et al, 2002).…”
Section: Discussionmentioning
confidence: 99%
“…Therefore, the predominant populations of LPMCs expressing MGL1 were considered to be macrophages, although they expressed CD11c. Because many reports previously suggested that IL-10 plays a key role in the modulation of DSS-induced experimental colitis in mice as well as Crohn's disease and ulcerative colitis in humans, 28 the expression of IL-10 mRNA by MGL1-positive macrophage-like cells was investigated. CD11b Ï© and F4/80-high cells, which consist of the MGL1-positive cells, were shown to contain significantly higher levels of IL-10 mRNA than F4/80-intermediate MGL1-negative cells ( Figure 2C).…”
Section: Properties Of Lamina Propria Mgl1-positive Cellsmentioning
confidence: 99%
“…Although their etiology is not yet fully known, the initiation and aggravation of the inflammatory process seem to be due to a dysregulated immune responses with a parallel increase in the expressions of pro-inflammatory cytokines, including tumor necrosis factor (TNF)-α, interleukin (IL)-1ÎČ, IL-6, and IL-8 (Hyun and Mayer 2006;Shih and Targan 2008). At the same time, deficiency of IL-10, an anti-inflammatory cytokine, seems to contribute to persistent intestinal inflammation (Li and He 2004;Shih and Targan 2008). Clinical reports have well document an increased risk of intestinal cancer in UC and CD patients (Askling et al 2001;Eaden et al 2001;Jess et al 2005).…”
Section: Introductionmentioning
confidence: 99%